Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo

Wells Fargo raised the firm’s price target on Kyverna Therapeutics (KYTX) to $33 from $31 and keeps an Overweight rating on the shares. The firm notes that mivocabtagene-autoleucel’s stiff person syndrome data is in line with its bull case and it believes shares should trade up into the mid-teens on the data. Wells thinks mivocabtagene-autoleucel could potentially benefit from priority review/CNPV given the high unmet need in stiff person syndrome.